The continuous progress in medicine has allowed semaglutide, a drug initially approved in 2017 for the treatment of type 2 diabetes, to gain greater significance by being approved in a higher dosage version and a new name, Wegovy, which was approved by the FDA on June 4, 2021. This approval from the Food and Drug Administration (FDA) has opened new possibilities, albeit posing significant challenges and risks.
Beyond Diabetes and Obesity: Emerging Use for Weight Loss.
While these medications were originally created to treat specific medical conditions such as type 2 diabetes and obesity, studies show an increase in their usage by individuals without these conditions. Semaglutide, in its various formulations, has proven effective for weight loss, with some individuals losing up to 15% of their body weight. However, experts warn of the danger of using these medications without medical supervision and the associated potential risks.
A Dual Challenge of Scarcity and Cost.
The growing demand for medications like Ozempic and Wegovy has led the FDA to include them in its list of scarce products. This phenomenon also extends to tirzepatide (Mounjaro), another medication for type 2 diabetes with weight-reducing properties. Additionally, the cost of these treatments hinders access for many patients.
It is important to note that semaglutide, like many medications, may not be covered by health insurance, raising concerns about accessibility and cost for those meeting FDA criteria for its use.
Semaglutide and Other GLP-1: What Are They, and Who Can Benefit?
Semaglutide belongs to the class of GLP-1 receptor agonists, which assist the pancreas in regulating insulin, slowing digestion, and controlling appetite. While initially designed for patients with type 2 diabetes, these medications can offer significant benefits to overweight adults.
Weight loss, even as little as 5%, can reduce cardiovascular risks and enhance overall health. However, it is crucial that their use is conducted under medical supervision and with an understanding of associated risks and benefits.
Off-Label Use: A Cautious Territory.
Despite potential benefits, addressing the off-label use of semaglutide in individuals without diabetes or obesity is necessary. Experts emphasize that these injections should not be considered quick solutions and require a long-term commitment. Discontinuing treatment could result in regaining lost weight.
Moreover, semaglutide presents challenging side effects, from common symptoms like nausea to more serious risks such as pancreatitis and thyroid tumors. Therefore, doctors recommend specialized consultation before embarking on these treatments.
These medications, including semaglutide and its variants, promise weight loss results, but their use must be carefully considered and supervised. Before deciding to initiate these treatments, consulting with healthcare professionals and assessing medical insurance coverage is crucial to ensure a safe and informed approach to health and well-being.
Our commitment at Rondon Brokerage is to our clients, and that’s why we bring you these publications to keep you informed about health and insurance matters.
